Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7300095 | 0.98 | LMNA (0.43) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL183881 | 0.98 | PKM (0.45) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6900749 | 0.85 | GAA (0.33) | SMN1; SMN2 | |
| SCHEMBL658298 | 0.82 | LMNA (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15922703 | 0.75 | EPHX1 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL294644 | 0.75 | EPHX1 (0.35) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21911249 | 0.74 | — | — | |
| SCHEMBL659081 | 0.73 | GRIN1 (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22193941 | 0.73 | PKM (0.31) | PKMGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15922722 | 0.73 | GRIN2D (0.36) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | claimed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | claimed |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID | 2009-01-01 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| CN-1282452-C | Use of aminoadamantane compounds as immunomodulators | MERZ & CO GMBH & CO (DE) | 2006-11-01 | — | — | CN | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1293201-A2 | Use of aminoadamantane compounds as immunoregulators | Merz Pharma GmbH & Co.KGaA (DE) | 2003-03-19 | — | — | EP | claimed |
| EP-0845984-B1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2003-03-12 | — | — | EP | claimed |
| US-6255348-B1 | AIDS THERAPY | MERZ + CO. GMBH & CO. (DE) | 2001-07-03 | — | — | US | claimed |
| US-6172116-B1 | NEUTROPHIL ACTIVATION; TREATING AUTOIMMUNE DISEASES | MERZ + CO. GMBH & CO. (DE) | 2001-01-09 | — | — | US | claimed |
| CN-1198669-A | Use of aminoadamantane compounds as immunomodulators | MERZ & CO GMBH & CO (DE) | 1998-11-11 | — | — | CN | claimed |
| EP-0845984-A1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ + CO. GmbH & Co. (DE) | 1998-06-10 | — | — | EP | claimed |
| WO-1997007791-A1 | USE OF AMINOADAMANTANE COMPOUNDS AS IMMUNOREGULATORS | MERZ + CO. GMBH & CO. (DE) | 1997-03-06 | — | — | WO | claimed |
| EP-0392059-B1 | USE OF ADAMANTANE DERIVATIVES IN THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | Merz & Co. GmbH & Co. (DE) | 1993-09-15 | — | — | EP | claimed |
| EP-0392059-A1 | Use of adamantane derivatives in the prevention and treatment of cerebral ischemia | Merz & Co. GmbH & Co. (DE) | 1990-10-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | PKM 1163/4885GRIN2D 12/4885GRIN3B 7/4885 |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | PKM 1163/4885GRIN2D 12/4885GRIN3B 7/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | PKM 4024/4885GRIN2D 140/4885GRIN3B 109/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | PKM 3751/4885GRIN2D 438/4885GRIN3B 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.